Company · CIK 1885827
Virax Biolabs Group Ltd
| CIK | 1885827 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2835 — In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | E9 |
| Business address | United Kingdom |
| Listed | VRAX (Nasdaq) |
| First annual or quarterly report | 2022-08-12 |
Offerings
6 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-275893 | 2023-12-05 | 2026-09-04 | 6 | |
| 333-297684 | 2026-07-24 | 2026-09-03 | 2 | |
| 333-292241 | 2025-12-18 | 2025-12-30 | 2 | |
| 333-270734 | 2023-03-22 | 2023-03-30 | 2 | |
| 333-268486 | 2022-11-21 | 2022-12-01 | 2 | |
| 333-263694 | 2022-03-18 | 2022-07-21 | 9 |
Filings
24| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-09-04 | 424B5Shelf takedown | 333-275893 | 0001193125-26-383658 |
| 2026-09-03 | EFFECTDeclared effective | 333-297684 | 9999999995-26-002878 |
| 2026-07-24 | F-3Shelf registered | 333-297684 | 0001193125-26-316130 |
| 2025-12-30 | EFFECTDeclared effective | 333-292241 | 9999999995-25-003963 |
| 2025-12-18 | F-3Shelf registered | 333-292241 | 0001193125-25-324805 |
| 2024-09-30 | 424B5Shelf takedown | 333-275893 | 0000950170-24-110179 |
| 2024-08-23 | 424B5Shelf takedown | 333-275893 | 0000950170-24-100026 |
| 2024-01-22 | 424B5Shelf takedown | 333-275893 | 0000950170-24-006155 |
| 2023-12-15 | EFFECTDeclared effective | 333-275893 | 9999999995-23-003660 |
| 2023-12-05 | F-3Shelf registered | 333-275893 | 0000950170-23-068150 |
| 2023-03-30 | EFFECTDeclared effective | 333-270734 | 9999999995-23-000763 |
| 2023-03-22 | F-1Registration filed | 333-270734 | 0000950123-23-002979 |
| 2022-12-01 | EFFECTDeclared effective | 333-268486 | 9999999995-22-003433 |
| 2022-11-21 | F-1Registration filed | 333-268486 | 0001193125-22-289176 |
| 2022-07-21 | 424B4Final prospectus | 333-263694 | 0001213900-22-040585 |
| 2022-06-30 | EFFECTDeclared effective | 333-263694 | 9999999995-22-001935 |
| 2022-06-27 | F-1/AAmendment | 333-263694 | 0001213900-22-035012 |
| 2022-06-24 | F-1/AAmendment | 333-263694 | 0001213900-22-034730 |
| 2022-06-21 | F-1/AAmendment | 333-263694 | 0001213900-22-033728 |
| 2022-06-07 | F-1/AAmendment | 333-263694 | 0001213900-22-031420 |
| 2022-05-11 | F-1/AAmendment | 333-263694 | 0001213900-22-025539 |
| 2022-04-25 | F-1/AAmendment | 333-263694 | 0001213900-22-021214 |
| 2022-03-18 | F-1Registration filed | 333-263694 | 0001213900-22-013563 |
| 2021-12-27 | DRSDraft made public | 377-05887 | 0001213900-21-067581 |